Loading, please wait ...
Skip


|  

News Analytics
360274?filename=360274 jpg&size=1.
MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy
GlobeNewswire News Room
Publish date unknown
LA JOLLA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) ...
Google
#AGITG
#ALS
#Calif
#Australia
#TheTokyoStockExchange
#TheSecuritiesandExchangeCommission
#PhD
#DCM
#MS
#Seretnyetal
#ARDS
#GLOBENEWSWIRE
#Form
#YuichiIwaki
#US
#NASH
#MediciNova
#GBM
#FDA
#COVID19
#UniversityofSydney
#JanetteVardy
#CIPN
#MIF
#CancerMedicine
#Vardy
#MD
#TheAustralasianGastroIntestinalTrialsGroup
#BCPIVSARS
#MediciNovaInc
#MNOV
#NASDAQ
#TheUniversityofSydney
#LAJOLLA

Subject Matter

  • Healthcare 64.06%
    • Hospitals, doctors and medical care 100.00%
  • Science and technology 35.94%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions